These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36836180)

  • 1. A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target.
    Li H; Tang Y; Hua L; Wang Z; Du G; Wang S; Lu S; Li W
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
    Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis.
    Chen Y; Wu Z; Yi X
    Sci Rep; 2024 Aug; 14(1):19071. PubMed ID: 39154046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK1 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Pan-Cancer, Especially in Gastrointestinal Tumors.
    Shen J; Gong X; Tan S; Zhang Y; Xia R; Xu S; Wang S; Zhou H; Jiang Y; Zhao T; Zhang Y; Tang H; Wang C
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38952160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.
    Liu J; Li W; Wu L
    Front Pharmacol; 2022; 13():950156. PubMed ID: 36046831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Analysis on the Oncogenic Role of Programmed Cell Death 10.
    Sun N; Li C; Teng Y; Deng Y; Shi L
    J Oncol; 2022; 2022():1242658. PubMed ID: 36276268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis.
    Zhang Y; Shang L; Han J; Shen X; Liu H; Yang J; Shi H
    Aging (Albany NY); 2023 Apr; 15(9):3427-3441. PubMed ID: 37179118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker.
    Gao B; Li X; Li S; Wang S; Wu J; Li J
    Phenomics; 2022 Feb; 2(1):33-49. PubMed ID: 36939765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.